PHILADELPHIA— The Gene Therapy Program Preclinical Vector Core in the Perelman School of Medicine at the University of Pennsylvania has been awarded a Gene Therapy Resource Program (GTRP) contract for a third consecutive five-year period from the National Heart, Lung and Blood Institute (NHLBI) of the National Institutes of Health (NIH).
The mission of the GTRP is to translate gene therapy research to the clinic. The $13 million contract will support the Core, which is directed by internationally renowned expert in gene therapy James M. Wilson, MD, PhD, the Rose H. Weiss Professor and Director of Penn’s Orphan Disease Center, and a professor of Medicine and Pediatrics, by providing preclinical vector production, analytics, and immunology services to approved scientific investigators from Penn and other institutions.
“The field of gene therapy is finally hitting its stride, and this is exactly the time for the NIH to be providing a robust infrastructure to promote the rapid acceleration of discoveries into clinical trials,” Wilson said. “The NHLBI is well positioned to do so through the GTRP, which we are delighted to participate in by providing high quality, state-of-the-art vectors for pre-clinical studies.”
The Core disseminates novel adeno-associated virus (AAV) vectors to researchers around the world. AAVs are small virus particles with a genome of single-stranded DNA that infect humans and some other primate species. AAVs are not currently known to cause disease. Recombinant AAV vectors are based on AAV viruses that have been engineered to express genes of interest including therapeutic genes for the treatment of inherited or acquired disease.
Over its first ten-year period of GTRP support, the Core completed over 100 requests for research-grade vector production and 10 requests for immunology services for developing gene therapies for a wide range of disorders, including cardiovascular, blood, lung, genetic, and infectious disease.
Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation’s first medical school) and the University of Pennsylvania Health System, which together form a $7.8 billion enterprise.
The Perelman School of Medicine has been ranked among the top medical schools in the United States for more than 20 years, according to U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $425 million awarded in the 2018 fiscal year.
The University of Pennsylvania Health System’s patient care facilities include: the Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center—which are recognized as one of the nation’s top “Honor Roll” hospitals by U.S. News & World Report—Chester County Hospital; Lancaster General Health; Penn Medicine Princeton Health; and Pennsylvania Hospital, the nation’s first hospital, founded in 1751. Additional facilities and enterprises include Good Shepherd Penn Partners, Penn Home Care and Hospice Services, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.
Penn Medicine is powered by a talented and dedicated workforce of more than 40,000 people. The organization also has alliances with top community health systems across both Southeastern Pennsylvania and Southern New Jersey, creating more options for patients no matter where they live.
Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2018, Penn Medicine provided more than $525 million to benefit our community.